Introduction
============

Variceal hemorrhage is one of the most lethal complications of portal hypertension.[@b1-tcrm-15-191] One-third of patients with esophageal varices will develop gastrointestinal bleed, and the risk of bleeding is correlated with increased high hepatic venous pressure gradient (HVPG).[@b2-tcrm-15-191] Therefore, in order to reduce mortality, it is of great significance to prevent variceal hemorrhage in the clinical management of patients with cirrhosis.

Among several recommended strategies, the most proposed treatment options are non-selective beta-blockers (NSBB) and endoscopic band ligation (EBL).[@b3-tcrm-15-191] In clinical practice, \<50% of patients with liver cirrhosis are sensitive to propranolol or nadolol with regard to hemodynamic aspects.[@b4-tcrm-15-191] Carvedilol, a third generation of NSBB, has been shown to possess an additional property of vasodilatation due to its intrinsic anti-α adrenergic activity.[@b5-tcrm-15-191] Carvedilol can effectively reduce cardiac output and splanchnic blood flow, while the action on α1 receptor leads to splanchnic vasoconstriction, decreasing HVPG and the incidence of related complications.[@b6-tcrm-15-191] Studies have demonstrated that carvedilol is superior to the traditional NSBB -- propranolol, in reducing portal pressure.[@b1-tcrm-15-191],[@b7-tcrm-15-191] In a meta-analysis based on five high-quality randomized controlled trials (RCTs), the proportion of patients with the use of carvedilol was much higher in achieving a target hemodynamic response (reduction ≥20% of baseline or to ≤12 mmHg) compared with those with propranolol.[@b8-tcrm-15-191]

Accumulating evidences indicate that endoscopic techniques are the effective intervention to prevent variceal bleeding in patients with severe or moderate varices.[@b9-tcrm-15-191] Compared with endoscopic injection sclerotherapy, EBL is a purely mechanical method of eradicating varices, with fewer endoscopic sessions and less frequent complications.[@b10-tcrm-15-191] Recently, several clinical trials have compared the effects of carvedilol with EBL for the primary or secondary prevention of variceal bleeding in patients with portal hypertension. However, the results from these trials were inconsistent. Therefore, we initiated this meta-analysis described here to assess the efficacy and safety of carvedilol use compared with EBL intervention for the prevention of variceal bleeding.

Methods
=======

This protocol was registered on the website of PROSPERO and the registration number was CRD42018106699.

Study eligibility
-----------------

Inclusion criteria: 1) study design: prospective RCTs; 2) participants: patients with a confirmed diagnosis of esophageal varices by endoscopy; 3) treatment group: carvedilol use; 4) comparison group: EBL intervention; and 5) outcomes: variceal bleeding, all-cause deaths, bleeding-related deaths, and adverse events.

Exclusion criteria: 1) studies that assessed the efficacy of carvedilol without controlled group; 2) retrospective clinical trials, letters to the editor, reviews, and case reports; and 3) studies published in languages other than English.

Search strategy
---------------

Pubmed, Embase, Medline, and The Cochrane Library were searched up to August 2018 to identify potential references by two independent investigators (Xuemei Jia and Yingyun Guo). Databases were searched through the following search terms: "carvedilol" AND "endoscopic band ligation". A manual search of the reference lists of related studies was also conducted by the two investigators. The database search was confined to clinical trials published in English language.

Data extraction and quality assessment
--------------------------------------

Data from the included studies were extracted by two independent researchers (Shan Tian and Ruixue Li). The following information was extracted from the selected studies: author, year, study period, number of patients, age, sex, presence of ascites, Child--Pugh class, follow-up time, and outcomes. It was decided to resolve any discrepancies through another investigator's final determination (Weiguo Dong). The guidelines of the Cochrane Handbook of Systematic Reviews of Interventions were applied to evaluate the quality assessment of included studies[@b11-tcrm-15-191] by the two researchers. The following items were assessed for every selected trial: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. For each item, the risk of bias was evaluated as either low, high, or unclear.

Statistical methods
-------------------

Relative ratios (RRs) with 95% CIs were applied to calculate with respect to dichotomous data. By using Review Manager software (RevMan, V.5.3, Copenhagen, Denmark, 2014),[@b11-tcrm-15-191] we performed statistical analysis according to the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions. We calculated the *χ*^2^ and *I*^2^ statistics to detect the heterogeneity among included studies. As for *I*^2^ statistic,[@b12-tcrm-15-191] 25%--50%, 50%--75%, and \>75% were separately regarded as low, moderate, and high heterogeneity. Random-effects model was used if substantial heterogeneity across studies was detected; otherwise, a fixed-effects model was adopted. Finally, potential reasons for heterogeneity were probed if significant heterogeneity was found. *P*\<0.05 was regarded as statistically significant.

Results
=======

Study identification and selection
----------------------------------

Our search identified 58 potential references through database search. A total of 35 reports were excluded due to duplication of publication. A total of 23 studies were considered for further analysis, and one study was added to our meta-analysis through reference lists.[@b13-tcrm-15-191] One study was a case report[@b14-tcrm-15-191] and one was a letter to the editor.[@b15-tcrm-15-191] One high-quality trial evaluated the effect of carvedilol in decreasing portal pressure without controlled group. Besides, 14 references were published as a form of review or meta-analysis. Finally, seven RCTs were included in the quantitative synthesis. The detailed flow diagram of the study selection process is shown in [Figure 1](#f1-tcrm-15-191){ref-type="fig"}.

Description of included studies
-------------------------------

Seven prospective RCTs were identified in our meta-analysis,[@b13-tcrm-15-191],[@b16-tcrm-15-191]--[@b21-tcrm-15-191] including 713 cases (359 patients in carvedilol group and 354 in EBL group) of patients with portal hypertension. The characteristics of the seven included trials are listed in [Table 1](#t1-tcrm-15-191){ref-type="table"}. The studies were conducted in Egypt (n=3),[@b13-tcrm-15-191],[@b18-tcrm-15-191],[@b19-tcrm-15-191] UK (n=2),[@b20-tcrm-15-191],[@b21-tcrm-15-191] Pakistan (n=1),[@b17-tcrm-15-191] and Austria (n=1).[@b16-tcrm-15-191] Six studies compared the efficacy and safety of carvedilol with EBL for prevention of the first variceal bleeding, while only one study compared the effects of carvedilol with EBL for the prevention of variceal rebleeding.[@b20-tcrm-15-191] As shown in [Table 1](#t1-tcrm-15-191){ref-type="table"}, these trials were conducted from 2000 to 2016. The mean age of participants ranged from 47.2 to 55 years, with a majority of male patients (59%) when the gender ratio was reported in six studies.[@b13-tcrm-15-191],[@b16-tcrm-15-191]--[@b18-tcrm-15-191],[@b20-tcrm-15-191],[@b21-tcrm-15-191] Four studies reported that the etiology of portal hypertension was chronic viral cirrhosis,[@b13-tcrm-15-191],[@b16-tcrm-15-191],[@b17-tcrm-15-191],[@b19-tcrm-15-191] while three trials demonstrated that alcohol liver disease was the primary reason for cirrhosis.[@b18-tcrm-15-191],[@b20-tcrm-15-191],[@b21-tcrm-15-191] The most common complication of cirrhosis -- ascites, was reported in six studies. A total of 43.34% of included patients (270/623) had concomitant ascites with different severity. Moreover, six trials applied the percentage of Child--Pugh class (A/B/C) to assess the liver function and the majority of patients were found to be class B or C (69.03%).[@b13-tcrm-15-191],[@b16-tcrm-15-191]--[@b19-tcrm-15-191],[@b21-tcrm-15-191] However, only one study used the form of mean (IQR) to represent the score of Child--Pugh class and the mean score was 9 (7.0--10.5) in carvedilol group and 9 (8.0--11.0) in EBL group.[@b20-tcrm-15-191] The mean time of follow-up ranged from 12 to 26.3 months. In general, the baseline features of included patients in carvedilol and EBL groups were basically comparable.

Treatment protocols
-------------------

Carvedilol was administered orally in patients in carvedilol group (n=359) in the seven studies. Patients in four studies were given a tablet of 6.25 mg/day and then slowly increased to 12.5 mg/day if tolerated. However, in one trial, patients in the carvedilol group were given a starting dosage of 6.25 mg/day, then increased to 12.5--50 mg/day to achieve a reduction in baseline heart rate by 25% but over 55 beats/min.[@b18-tcrm-15-191] Another two clinical trials used 25 mg/day as long-run dose if patients could tolerate.[@b13-tcrm-15-191],[@b16-tcrm-15-191] The endpoint of EBL in all included studies was obliteration of varices except for one trial, which defined endpoint of EBL as esophageal varices being either grade I or complete obliteration.[@b19-tcrm-15-191] The interval of EBL in selected studies varied from 2 to 4 weeks.

Among seven included trials, five studies were associated with a low risk of bias,[@b16-tcrm-15-191]--[@b18-tcrm-15-191],[@b20-tcrm-15-191],[@b21-tcrm-15-191] one study[@b19-tcrm-15-191] was assessed as unclear risk of bias, and one trial was evaluated as high risk of bias.[@b13-tcrm-15-191] [Figure 2](#f2-tcrm-15-191){ref-type="fig"} shows the quality of the included studies as assessed by Review Manager software.

Outcome measures
----------------

### Variceal bleeding

Seven studies evaluated variceal bleeding as an outcome measure. A total of 46 patients had variceal hemorrhage in the carvedilol group (12.81%), while 52 patients had it in the EBL group (14.69%). The rate of variceal bleeding ranged from 5% to 36.4% for patients with carvedilol use, and from 10% to 35.5% in patients with EBL. Four clinical trials showed that the carvedilol group had lower variceal bleeding rate than the EBL group. However, two studies demonstrated that variceal bleeding rate was lower in EBL group than in carvedilol group.[@b18-tcrm-15-191],[@b20-tcrm-15-191] Only one trial reported that variceal bleeding rate was equal in two groups.[@b19-tcrm-15-191] When we pooled the outcome of variceal bleeding into meta-analysis, no significant difference was noted between two groups (RR =0.86, 95% CI =0.60--1.23), as shown in [Figure 3A](#f3-tcrm-15-191){ref-type="fig"}. Moreover, statistical test indicated that the studies did not have significant heterogeneity (*I*^2^=11%, *P*=0.35). Therefore, the results were calculated according to the fixed-effect method. There was no evidence of publication bias through the funnel plot ([Figure 4A](#f4-tcrm-15-191){ref-type="fig"}).

However, in the seven selected trials, only one study assessed variceal rebleeding as an outcome measure.[@b20-tcrm-15-191] So, we performed a subgroup analysis through first and second prevention of variceal bleeding. Six studies evaluated first prevention of hemorrhage as an outcome measure. No significant difference was observed through the fixed-effect model (RR =0.81, 95% CI =0.53--1.24, *I*^2^=22%, [Figure 3B](#f3-tcrm-15-191){ref-type="fig"}). No evidence of publication bias was detected through the funnel plot ([Figure 4B](#f4-tcrm-15-191){ref-type="fig"}). As for the second prevention of hemorrhage, only one trial reported that 64 cases of patients with portal hypertension were randomized to this multicenter study.[@b20-tcrm-15-191] Variceal rebleeding occurred in 12 patients (36.4%) in the carvedilol group and 11 patients (35.5%) in the EBL group. However, this difference was also not significant according to the chi-squared test (*P*=0.857).

### All-cause and bleeding-related deaths

Three trials did not report the all-cause and bleeding-related deaths due to the relatively short follow-up time (12 months).[@b16-tcrm-15-191],[@b18-tcrm-15-191],[@b19-tcrm-15-191] There were 49 deaths (21.30%) in the carvedilol group and 52 (23.53%) in the EBL group. There was no significant difference in the incidence of all-cause deaths between carvedilol and EBL groups (RR =0.82, 95% CI =0.44--1.53, [Figure 5A](#f5-tcrm-15-191){ref-type="fig"}). Due to the significant heterogeneity in the four studies (*I*^2^=66%, *P*=0.03), the random-effect model was applied. Moreover, bleeding-related deaths were also assessed as an outcome measure to compare the safety of carvedilol use vs EBL intervention. The number of patients who died from bleeding in carvedilol group (12/230) was equal to that in the EBL group (12/221). When we pooled this outcome into meta-analysis, we found that no significant difference was noted between two groups (RR =0.85, 95% CI =0.39--1.87), as shown in [Figure 5B](#f5-tcrm-15-191){ref-type="fig"}. No obvious heterogeneity (*I*^2^=42%, *P*=0.16) was detected through statistical tests.

### Adverse events

Adverse events were confined to side effects of carvedilol or EBL, not related to the progression of chronic liver disease or symptoms of variceal bleeding. Five studies have reported the adverse events.[@b13-tcrm-15-191],[@b17-tcrm-15-191],[@b18-tcrm-15-191],[@b20-tcrm-15-191],[@b21-tcrm-15-191] A total of 104 adverse events (104/296) occurred in the carvedilol group, while 109 (109/296) occurred in the EBL group, as shown in [Table 2](#t2-tcrm-15-191){ref-type="table"}. Although the adverse events were different in every included study, the vast majority was systematic hypotension in the carvedilol group and chest pain caused by mechanical injury in the EBL group. We tried to pool adverse events into meta-analysis and this index did not show any significant difference between two groups (RR =1.32, 95% CI =0.75--2.31, [Figure 6A](#f6-tcrm-15-191){ref-type="fig"}). Due to the obvious heterogeneity (*I*^2^=81%, *P*=0.0003), we conducted sensitivity analysis by excluding one study at a time and recalculating the pooled RRs for the remaining four studies. When we excluded Shah et al[@b17-tcrm-15-191] 2013, we found that the heterogeneity was significantly decreased (*I*^2^=54%, *P*=0.09, [Figure 6B](#f6-tcrm-15-191){ref-type="fig"}). This trial divided adverse events into serious adverse events (2 in carvedilol group and 18 in EBL group) and non-serious adverse events (48 in carvedilol group, 58 in EBL group).[@b17-tcrm-15-191] The heterogeneity was moderate and not low even after sensitivity analysis due to the diversity of adverse events reported in five clinical trials.

Discussion
==========

Portal hypertension causes some fatal complications in patients with liver cirrhosis, such as variceal bleeding and hepatic encephalopathy. Prevention options of variceal bleeding with higher efficacy, less side effects, and lower cost are urgently needed in the clinical management of patients with portal hypertension.[@b22-tcrm-15-191],[@b23-tcrm-15-191] Currently, most meta-analysis was focused on comparing the efficacy of propranolol with EBL,[@b9-tcrm-15-191],[@b24-tcrm-15-191],[@b25-tcrm-15-191] or comparing the efficacy and safety of carvedilol with pro-pranolol.[@b8-tcrm-15-191] As this newer NSBB was widely used in the prevention of variceal bleeding with fewer side effects and better tolerance in contrast to propranolol, it is significant to explore the question as follows: whether carvedilol use is more suitable for prevention of variceal bleeding than EBL intervention.

To our knowledge, this is the first meta-analysis to date comparing carvedilol use with EBL intervention for the prevention of esophageal variceal bleeding. From the seven included studies, we observed that the rate of variceal bleeding was lower in carvedilol group than in EBL group. However, there was no significant difference from the forest plot (RR =0.86, 95% CI =0.60--1.23, *I*^2^=11%).

Carvedilol is a potent portal hypotensive agent with additional anti-α1 receptor activity, which is widely applied in the management of portal hypertension, hypertension, heart failure, and ischemic heart disease. Study has shown that carvedilol reduces portal pressure not only through lowering portal-collateral blood flow (as propranolol) but also through decreasing the hepatic vascular resistance.[@b4-tcrm-15-191] The superiority of carvedilol over propranolol in reducing HVPG is associated with the α1 blocking effect, which could reduce intra-hepatic resistance.[@b26-tcrm-15-191] Moreover, recent studies have demonstrated that this agent possesses antioxidant properties, exerts beneficial effects on mitochondrial function, and could decrease the resistance of insulin.[@b27-tcrm-15-191]--[@b29-tcrm-15-191] Hence, the comprehensive mechanisms of action of carvedilol make it a promising agent for the prevention of variceal bleeding in patients with cirrhosis.

Our meta-analysis did not show additional benefits of carvedilol over EBL, neither for the first prevention nor the second prevention of esophageal variceal bleeding. The fact that no significant difference is observed between the two options with regard to variceal bleeding does not necessarily indicate that the two kinds of therapy are equally effective. Carvedilol could reduce portal pressure with fewer complications, while EBL is a kind of invasive intervention without changing the potential pathophysiological mechanisms and only last for a short period of time. A retrospective study demonstrated that carvedilol was not associated with increased risk of mortality in decompensated cirrhosis patients and long-term carvedilol therapy could improve the survival of patients with cirrhosis.[@b30-tcrm-15-191] Moreover, a prospective study conducted by Kirnake et al showed that 76% patients maintained their hemodynamic response to carvedilol through intention-to-treat analysis and carvedilol treatment was associated with favorable clinical survival in patients with portal hypertension.[@b4-tcrm-15-191] Possible reasons that the benefits of carvedilol in the prevention of variceal bleeding did not translate into decreased rate of variceal bleeding are as follows: first, carvedilol is a potent portal hypotensive agent with multiple effects and these effects will be more obvious in the long run. However, most included studies have followed up for 1--2 years and three trials have followed up only for 1 year. Second, over the past decades, EBL technique has been well grasped by more and more clinicians and the higher variceal eradication rate in the EBL group may signify the lower variceal bleeding rate.

We have noted that carvedilol did not gain additional benefits in reducing adverse events as compared to EBL for the prevention of variceal bleeding. From the five included studies, we found that adverse effects occurred with similar incidence both in the carvedilol and the EBL groups. In carvedilol group, the most common serious adverse event was symptomatic hypotension. No patient in carvedilol group was reported to experience serious sodium-water retention after the use of carvedilol. However, the incidence of symptomatic hypotension due to the use of carvedilol will be decreased by starting at a very low dose (6.25 mg/day) and careful titration by gradually increasing up to 12.5 mg/day. Maharaj et al hold the view that the typical threshold for carvedilol toxicity in overdose is 50 mg.[@b14-tcrm-15-191] Moreover, hemodynamic monitoring is useful to reduce the incidence of symptomatic hypotension during the period of carvedilol use. Chest pain was the most common serious adverse event in EBL group, followed by esophageal ulcer. These complications in EBL group often require urgent hospitalization and could be lethal if not handled properly. However, the evaluation of adverse events in meta-analysis of included trials is often difficult due to lack of a unified definition, which is more likely to cause no significant difference of adverse events between two groups.[@b30-tcrm-15-191]

Several limitations still exist in our meta-analysis. First, we cannot deny the fact that the quality of some selected studies was relatively low. As carvedilol is easily differentiate from EBL operation for patients, it is hard to perform blinding for trials. Subsequently, with respect to subgroup analysis according to first and second prevention, we cannot perform a meta-analysis of second prevention due to only one available study. Third, the selected references had varying designs, including differences in dose of carvedilol, frequency of EBL, and follow-up time, which may affect the outcomes of the selected trials.

Conclusion
==========

Our study demonstrates that no significant difference exists between carvedilol use and EBL groups in the prophylaxis of variceal bleeding. High-quality clinical trials with adequate bias control and sufficient follow-up are required in order to determine the long-term effects of both treatments.
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![Fixed-effect model of variceal bleeding.\
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**Notes:** (**A**) For first and second prophylaxis of variceal bleeding. (**B**) For first prophylaxis of variceal bleeding.\
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**Notes:** (**A**) All-cause deaths. (**B**) Bleeding-related deaths.\
**Abbreviation:** EBL, endoscopic band ligation.](tcrm-15-191Fig5){#f5-tcrm-15-191}

![Forest plots of adverse events.\
**Notes:** (**A**) Five studies. (**B**) Four studies.\
**Abbreviation:** EBL, endoscopic band ligation.](tcrm-15-191Fig6){#f6-tcrm-15-191}

###### 

Clinical features of patients in the included studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author year                               Group   Study period          Patients (n)   Age (years)   Men vs women   Ascites (n)   Child-- Pugh class   Interventions                                                 Follow-up (months)
  ----------------------------------------- ------- --------------------- -------------- ------------- -------------- ------------- -------------------- ------------------------------------------------------------- --------------------
  Elrahim et al,[@b18-tcrm-15-191] 2018     C\      2015--5 to 2016--6    84\            51.2±11.0\    34:66\         26\           30/28/42\            6.25 mg/d initiation Up to 12.5--50 mg/d\                     12\
                                            EBL                           88             50.6±5.9      38:62          44            20/24/56             EBL/2 weeks until eradication of varices                      12

  Stanley et al,[@b20-tcrm-15-191] 2014     C\      2006--6 to 2012--6    33\            51.4±10.8\    22:11\         12\           9 (7.0--10.5)\       6.25 mg/d for 1 week, then increased to 12.5 mg/d\            26.3 (10.2--46.6)\
                                            EBL                           31             49.6±12.87    21:10          12            9 (8.0--11.0)        EBL at 1 week, then 2 weekly                                  26.3 (10.2--46.6)

  Shah et al,[@b17-tcrm-15-191] 2014        C\      2007--5 to 2011--9    82\            48.3±11.3\    59:23\         33\           37/35/10\            6.25 mg/d initiation then increased to 6.25 mg twice a day\   13.2±11.7\
                                            EBL                           86             47.2±13.2     63:23          32            37/37/12             EBL/3 weeks until eradication of varices                      13.4±12.4

  Tripathi et al,[@b21-tcrm-15-191] 2009    C\      2000--4 to 2006--5    77\            54.2±9.4\     54:23\         49\           38/24/38\            6.25 mg/d initiation, then increased to 12.5 mg/d\            26.2±22.1\
                                            EBL                           75             54.5±11.1     55:20          53            35/25/40             EBL/2 weeks until eradication of varices                      25.5±21.9

  Elnadry,[@b13-tcrm-15-191] 2010           C\      2008--2 to 2009--3    20\            50.1±6.2\     11:9\          NR\           12/4/4\              12.5 mg increased after 2 weeks to reach 25 mg daily\         12\
                                            EBL                           20             51.5±8.1      13:7           NR            8/4/8                NR                                                            12

  Ahmad et al,[@b19-tcrm-15-191] 2012       C\      2008--12 to 2011--9   25\            NR\           NR\            NR\           9/7/9\               6.25 mg/d for 1--2 weeks, increased to 12.5 mg/d\             12\
                                            EBL                           25             NR            NR             NR            9/6/10               EBL/2--4 weeks until eradication of varices                   12

  Reiberger et al,[@b16-tcrm-15-191] 2013   C\      2008--2012            38\            55±11\        28:10\         4\            26/10/2\             6.25 mg/d and increased to 25 mg/d\                           24\
                                            EBL                           29             50±14         23:6           5             16/11/2              EBL/2--4 weeks until eradication of varices                   24
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** C, carvedilol; EBL, endoscopic band ligation; NR, not reported; mg/d, mg/day.

###### 

Outcomes reported in the included studies

  Author, year                                Group   Variceal bleeding (n/N)   All-cause mortality (n/N)   Bleeding-related mortality (n/N)   Adverse events (n/N)
  ------------------------------------------- ------- ------------------------- --------------------------- ---------------------------------- ----------------------
                                                                                                                                               
  Abd Elrahim et al,[@b18-tcrm-15-191] 2018   C       13/84                     NR                          NR                                 12/84
  EBL                                         9/88    NR                        NR                          5/84                               
  Stanley et al,[@b20-tcrm-15-191] 2014       C       12/33                     9/33                        5/33                               19/33
  EBL                                         11/31   16/31                     1/31                        18/31                              
  Shah et al,[@b17-tcrm-15-191] 2014          C       7/82                      16/82                       4/82                               50/82
  EBL                                         6/86    11/86                     4/86                        75/86                              
  Tripathi et al,[@b21-tcrm-15-191] 2009      C       7/77                      20/77                       2/77                               10/77
  EBL                                         14/75   16/75                     2/75                        6/75                               
  Elnadry et al,[@b13-tcrm-15-191] 2010       C       2/20                      NR                          NR                                 13/20
  EBL                                         2/20    NR                        NR                          5/20                               
  Ahmad et al,[@b19-tcrm-15-191] 2012         C       2/25                      NR                          NR                                 NR
  EBL                                         3/25    NR                        NR                          NR                                 
  Reiberger et al,[@b16-tcrm-15-191] 2013     C       3/38                      4/38                        1/38                               NR
  EBL                                         7/29    9/29                      5/29                        NR                                 

**Abbreviations:** C, carvedilol; EBL, endoscopic band ligation; NR, not reported.
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